CA2449910A1 - Use of glycoprotein for the treatment and re-epithelialisation of wounds - Google Patents
Use of glycoprotein for the treatment and re-epithelialisation of wounds Download PDFInfo
- Publication number
- CA2449910A1 CA2449910A1 CA002449910A CA2449910A CA2449910A1 CA 2449910 A1 CA2449910 A1 CA 2449910A1 CA 002449910 A CA002449910 A CA 002449910A CA 2449910 A CA2449910 A CA 2449910A CA 2449910 A1 CA2449910 A1 CA 2449910A1
- Authority
- CA
- Canada
- Prior art keywords
- glycoprotein
- wounds
- antarticine
- treatment
- epithelialisation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 16
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 16
- 206010052428 Wound Diseases 0.000 title claims abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 4
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 230000000699 topical effect Effects 0.000 claims abstract 2
- 241000519590 Pseudoalteromonas Species 0.000 claims description 5
- 241000519593 Pseudoalteromonas antarctica Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 101150114843 Mgll gene Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the use of a glycoprotein, which is produced by Pseudoalteromonas antarctica and which comprises 14 % carbohydrates and 86 % protein, in the preparation of pharmaceutical, veterinary and cosmetic compositions for topical or mucosal application. Said glycoprotein is used f or the treatment and re-epithelialisation of wounds and in the preparation of cosmetic compositions used to treat the skin, hair and nails.
Description
USE OF A GLYCOPROTEIN FOR TREATMENT AND RE-EPITHELIZALIZATION OF
WOUNDS
OBJECT OF THE INVENTION
The present invention relates to the use of a glycoprotein known as Antarticine - NF3 for preparing pharmaceutical, veterinarian and cosmetic compositions for treatment and re-epithelizalization of wounds.
STATE OF THE ART
Antarticine - NF3 is a glycoprotein produced by Pseudoalteromonas antartica, a Gram-negative bacteria isolated from the Antarctic Ocean. This aerobic heterotropic bacterium has a single polar flagellum and produces a hexapolymeric glycoprotein (Antarticine - NF3) composed of 14% carbohydrate and 86% protein that completely surround it. Pseudoalteromonas antartica is perfectly adapted to the low temperatures of the Antarctic environment and withstands high salt concentrations.
Antarticine - NF3 in solution forms regular aggregates by self-assembly. A
gradual increase in the concentration of a solution of this glycoprotein causes a gradual reduction of the surface tension of the solution. In addition, Antarticine -NF3 is known 2 0 for its great affinity to phosphatidylcholine liposome; coating them and protecting them from the permeabilisation effect of surfactants such as SDS, as described in W098/42731. In addition, Antarticine - NF3 is known for inducing nucleation of ice and preventing the growth of large hexagonal ice crystals. These data suggest that Antarticine - NF3 is responsible for the adaptation of Pseudoalteromonas antartica to the environmental conditions of its Antarctic habitat.
Furthermore, keratinocytes are a type of cell found in the epidermis, forming its deepest layer. Keratinocytes generate the outer skin layer (corneal stratum) by multiplication and modification of their structure until forming the layer of mature, keratinocytised cells on the surface of the skin. The speed of healing of wounds is 3 0 influenced, among other factors, by the rate of proliferation and migration of keratinocytes. Any factor that enhances one of these processes will favour the healing and scarring process for wounds.
DESCRIPTION OF THE INVENTION
As a result of our investigations we have found that, surprisingly, the soluble glycoprotein from Pseudoalteromonas antartica known as Antarticine - NF3, which consists of 14% carbohydrates and 86% protein, selectively improves the adhesion of human dermal fibroblasts and promotes the cellular growth of human epidermal keratinocytes. Thus, Antarticine - NF3 has surprisingly revealed itself as a good agent for improving scar formation in wounds.
Thus, the object of the present invention is the use of Antarticine - NF3 in solutions or acceptable galenical formulations for use in the treatment and re-epithelization of wounds in the pharmaceutical and veterinary fields, as well as for to cosmetic regeneration treatments. The concentrations used of Antarticine -NF3 are between 100 mgll and 1 fglml, and more specifically between 10 mglml and 0.1 ng/ml.
As a complement of the description being made and in order to aid a better understanding of the characteristics of the invention, a few examples are provided below for purposes of illustration only and in a non-limiting sense. This invention should not be considered as limited by the realizations described.
Example 1: in vitro cytotoxicity Experiments were carried out with the WST-1 test, which measures the activity of mitochondrial dehydrogenases in a non-radioactive calorimeter test using formazan salts. Different concentrations of glycoprotein were tested (between 1 mglml and 0.01 Nglml). NaCI 0.01 M was used as a negative control and SDS 0.02% was used as a positive control.
The results obtained are shown in the following table:
Concentration Result Result on HEK
tested on HDF
Control 0.46 0.92 Negative control (NaCI)0.01 M 0.43 0.7 Positive control (SDS)0.02% 0.17 0.2 1 fg - 0.78 0.1 pg - 0.92 O.Ong 1 0.44 0.92 1 ng 0.43 1.02 0.1 Ng 0.41 0.97 10 Ng 0.42 0.8 1 mg 0.44 0.81 As can be seen in the above table, the cytotoxicity tests revealed that Antarticine - NF3 does not show toxicity in human epidermal keratinocytes (HEK), nor in human dermal fibroblasts (HDF).
Example 2: effect on cellular adhesion Cellular adhesion tests in vitro revealed that Antarticine - NF3 has a specific effect on the adhesion of HDF. HDF cells showed a significant growth in cellular adhesion when growing on substrates coated with 1 mg/ml of Antarticine - NF3 after 2 and 5 hours of culture.
The results obtained for HDF are shown in the following table:
Concentration Time 2 hours Time 5 hours tested Control 0.1 0.13 Glycoprotein 0.001 mglml 0.11 0.24 1 mg/ml 0.24 0.28 The results obtained for HEK are shown in the following table:
Concentration Time 2 hours Time 5 hours tested Control 0.09 0.15 Glycoprotein 0.001 mglml 0.11 0.17 ~
1 mglml 0.15 0.19 As may be seen, in similar culture conditions the effect seen on HEK is not statistically significant.
Example 3: effect on cell growth 2 0 Experiments on in vitro cell growth conducted with the crystal violet elution method revealed that Antarticine - NF3 at different concentrations, in the presence or absence of a minimal amount of foetal cow serum (2%FCS) stimulates the growth of HEK cells, as shown in the following table:
WOUNDS
OBJECT OF THE INVENTION
The present invention relates to the use of a glycoprotein known as Antarticine - NF3 for preparing pharmaceutical, veterinarian and cosmetic compositions for treatment and re-epithelizalization of wounds.
STATE OF THE ART
Antarticine - NF3 is a glycoprotein produced by Pseudoalteromonas antartica, a Gram-negative bacteria isolated from the Antarctic Ocean. This aerobic heterotropic bacterium has a single polar flagellum and produces a hexapolymeric glycoprotein (Antarticine - NF3) composed of 14% carbohydrate and 86% protein that completely surround it. Pseudoalteromonas antartica is perfectly adapted to the low temperatures of the Antarctic environment and withstands high salt concentrations.
Antarticine - NF3 in solution forms regular aggregates by self-assembly. A
gradual increase in the concentration of a solution of this glycoprotein causes a gradual reduction of the surface tension of the solution. In addition, Antarticine -NF3 is known 2 0 for its great affinity to phosphatidylcholine liposome; coating them and protecting them from the permeabilisation effect of surfactants such as SDS, as described in W098/42731. In addition, Antarticine - NF3 is known for inducing nucleation of ice and preventing the growth of large hexagonal ice crystals. These data suggest that Antarticine - NF3 is responsible for the adaptation of Pseudoalteromonas antartica to the environmental conditions of its Antarctic habitat.
Furthermore, keratinocytes are a type of cell found in the epidermis, forming its deepest layer. Keratinocytes generate the outer skin layer (corneal stratum) by multiplication and modification of their structure until forming the layer of mature, keratinocytised cells on the surface of the skin. The speed of healing of wounds is 3 0 influenced, among other factors, by the rate of proliferation and migration of keratinocytes. Any factor that enhances one of these processes will favour the healing and scarring process for wounds.
DESCRIPTION OF THE INVENTION
As a result of our investigations we have found that, surprisingly, the soluble glycoprotein from Pseudoalteromonas antartica known as Antarticine - NF3, which consists of 14% carbohydrates and 86% protein, selectively improves the adhesion of human dermal fibroblasts and promotes the cellular growth of human epidermal keratinocytes. Thus, Antarticine - NF3 has surprisingly revealed itself as a good agent for improving scar formation in wounds.
Thus, the object of the present invention is the use of Antarticine - NF3 in solutions or acceptable galenical formulations for use in the treatment and re-epithelization of wounds in the pharmaceutical and veterinary fields, as well as for to cosmetic regeneration treatments. The concentrations used of Antarticine -NF3 are between 100 mgll and 1 fglml, and more specifically between 10 mglml and 0.1 ng/ml.
As a complement of the description being made and in order to aid a better understanding of the characteristics of the invention, a few examples are provided below for purposes of illustration only and in a non-limiting sense. This invention should not be considered as limited by the realizations described.
Example 1: in vitro cytotoxicity Experiments were carried out with the WST-1 test, which measures the activity of mitochondrial dehydrogenases in a non-radioactive calorimeter test using formazan salts. Different concentrations of glycoprotein were tested (between 1 mglml and 0.01 Nglml). NaCI 0.01 M was used as a negative control and SDS 0.02% was used as a positive control.
The results obtained are shown in the following table:
Concentration Result Result on HEK
tested on HDF
Control 0.46 0.92 Negative control (NaCI)0.01 M 0.43 0.7 Positive control (SDS)0.02% 0.17 0.2 1 fg - 0.78 0.1 pg - 0.92 O.Ong 1 0.44 0.92 1 ng 0.43 1.02 0.1 Ng 0.41 0.97 10 Ng 0.42 0.8 1 mg 0.44 0.81 As can be seen in the above table, the cytotoxicity tests revealed that Antarticine - NF3 does not show toxicity in human epidermal keratinocytes (HEK), nor in human dermal fibroblasts (HDF).
Example 2: effect on cellular adhesion Cellular adhesion tests in vitro revealed that Antarticine - NF3 has a specific effect on the adhesion of HDF. HDF cells showed a significant growth in cellular adhesion when growing on substrates coated with 1 mg/ml of Antarticine - NF3 after 2 and 5 hours of culture.
The results obtained for HDF are shown in the following table:
Concentration Time 2 hours Time 5 hours tested Control 0.1 0.13 Glycoprotein 0.001 mglml 0.11 0.24 1 mg/ml 0.24 0.28 The results obtained for HEK are shown in the following table:
Concentration Time 2 hours Time 5 hours tested Control 0.09 0.15 Glycoprotein 0.001 mglml 0.11 0.17 ~
1 mglml 0.15 0.19 As may be seen, in similar culture conditions the effect seen on HEK is not statistically significant.
Example 3: effect on cell growth 2 0 Experiments on in vitro cell growth conducted with the crystal violet elution method revealed that Antarticine - NF3 at different concentrations, in the presence or absence of a minimal amount of foetal cow serum (2%FCS) stimulates the growth of HEK cells, as shown in the following table:
Concentration Time 0 hoursTime 24 Time 48 tested hours hours Control 0.2 0.16 0.58 Glycoprotein10 NgImL 0.15 0.78 0.1 pglmL 0.16 0.77 0.001 NgImL 0.18 0.77 While similar experiments conducted with HDF cells did not show relevant results, as shown on the following table:
Concentration Time 0 hoursTime 24 Time 48 tested hours hours Control 0.21 0.16 0.25 Glycoprotein10 pg/mL 0.175 0.26 0.1 Ng/mL 0.17 0.248 0.001 Ng/mL 0.175 0.249 Example 4: effect on in vitro wound regeneration Experiments for regeneration of wounds in vitro were conducted in cultures of differentiated HEK cells, in the presence and absence of FCS. The duration of the tests was seven days.
l0 Concentrations of Antarticine - NF3 above 0.1 ng/ml showed a positive effect on wound regeneration when compared to control cultures; this effect of Antarticine -NF3 on wound regeneration in vitro can be seen in figure 1 for a concentration of 0.1 Ng/mL.
Concentration Time 0 hoursTime 24 Time 48 tested hours hours Control 0.21 0.16 0.25 Glycoprotein10 pg/mL 0.175 0.26 0.1 Ng/mL 0.17 0.248 0.001 Ng/mL 0.175 0.249 Example 4: effect on in vitro wound regeneration Experiments for regeneration of wounds in vitro were conducted in cultures of differentiated HEK cells, in the presence and absence of FCS. The duration of the tests was seven days.
l0 Concentrations of Antarticine - NF3 above 0.1 ng/ml showed a positive effect on wound regeneration when compared to control cultures; this effect of Antarticine -NF3 on wound regeneration in vitro can be seen in figure 1 for a concentration of 0.1 Ng/mL.
Claims (4)
1. Use of a glycoprotein produced by Pseudoalteromonas antartica and consisting of 14% carbohydrates and 86% protein in the preparation of pharmaceutical, veterinary and cosmetic compositions for topical or mucous application in the treatment and re-epithelisation of wounds.
2. Use of a glycoprotein according to claim 1 in the preparation of cosmetic compositions for treatment of skin, hair or nails.
3. Use according to either of claims 1 and 2, wherein said glycoprotein is used in concentrations between 100 mg/ml and 1 ng/ml.
4. Use according to claim 3, wherein said glycoprotein is preferably used in concentrations between 10 mg/ml and 0.1 ng/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200101383 | 2001-06-14 | ||
| ES200101383A ES2181592B1 (en) | 2001-06-14 | 2001-06-14 | USE OF GLICOPROTEIN FOR THE TREATMENT AND RE-EPITHELIZATION OF WOUNDS |
| PCT/ES2002/000281 WO2002102406A1 (en) | 2001-06-14 | 2002-06-07 | Use of glycoprotein for the treatment and re-epithelialisation of wounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2449910A1 true CA2449910A1 (en) | 2002-12-27 |
| CA2449910C CA2449910C (en) | 2013-01-08 |
Family
ID=8498066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2449910A Expired - Lifetime CA2449910C (en) | 2001-06-14 | 2002-06-07 | Use of glycoprotein for the treatment and re-epithelialisation of wounds |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7022668B2 (en) |
| EP (1) | EP1402898B1 (en) |
| JP (1) | JP4252444B2 (en) |
| KR (1) | KR20040030675A (en) |
| AT (1) | ATE285787T1 (en) |
| BR (1) | BRPI0210428B8 (en) |
| CA (1) | CA2449910C (en) |
| DE (1) | DE60202474T2 (en) |
| ES (2) | ES2181592B1 (en) |
| MX (1) | MXPA03011622A (en) |
| PT (1) | PT1402898E (en) |
| WO (1) | WO2002102406A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100784486B1 (en) * | 2007-01-08 | 2007-12-11 | 주식회사 에스티씨나라 | Cosmetic composition for skin tightening and skin tightening method using same |
| KR101126314B1 (en) | 2007-11-15 | 2012-03-23 | 한국해양연구원 | Novel Cryoprotective Exopolysaccharide |
| ES2336995B1 (en) * | 2008-10-13 | 2011-02-09 | Lipotec, S.A. | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION FOR SKIN CARE, HAIR LEATHER AND NAILS. |
| ES2390033B1 (en) | 2010-11-30 | 2013-10-31 | Lipotec S.A. | EXOPOLISACÁRIDO FOR THE TREATMENT AND / OR CARE OF SKIN, MUCOSAS, HAIR AND / OR NAILS. |
| WO2013121002A1 (en) | 2012-02-16 | 2013-08-22 | Arquebio, S. L. | Microorganism-free extract from hypersaline aqueous environments and process for its preparation |
| EP3062889A2 (en) | 2013-11-01 | 2016-09-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| CN116370397A (en) * | 2014-10-31 | 2023-07-04 | 利普泰个人股份有限公司 | Cosmetic and/or pharmaceutical composition comprising bacterial extracellular products from pseudoalteromonas antarctica and use thereof |
| EP3165233B1 (en) | 2015-08-28 | 2021-08-18 | Latvijas Universitate | Biomaterial for treatment of acute and chronic skin wounds |
| KR102311724B1 (en) | 2017-09-15 | 2021-10-13 | (주)아모레퍼시픽 | Composition for whitening of skin comprising culture or its extract of pseudoalteromonas peptidolytica |
| KR102395984B1 (en) | 2017-09-27 | 2022-05-11 | (주)아모레퍼시픽 | Composition for whitening of skin comprising culture or its extract of pseudoalteromonas carrageenovora |
| EP3790568A1 (en) * | 2018-05-08 | 2021-03-17 | Gat Biosciences, S.L. | Imac-enriched microalgal culture supernatant and uses thereof |
| FR3150433A1 (en) * | 2023-06-30 | 2025-01-03 | L'oreal | Composition comprising a glycoprotein and a coloring agent. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2126516B1 (en) * | 1997-03-26 | 1999-12-01 | Univ Barcelona | GLYCOPROTEIN FOR PROTECTION OF LIPOSOMES. |
-
2001
- 2001-06-14 ES ES200101383A patent/ES2181592B1/en not_active Expired - Fee Related
-
2002
- 2002-06-07 ES ES02738185T patent/ES2236525T3/en not_active Expired - Lifetime
- 2002-06-07 EP EP02738185A patent/EP1402898B1/en not_active Expired - Lifetime
- 2002-06-07 AT AT02738185T patent/ATE285787T1/en active
- 2002-06-07 KR KR10-2003-7016338A patent/KR20040030675A/en not_active Application Discontinuation
- 2002-06-07 BR BRPI0210428-8 patent/BRPI0210428B8/en not_active IP Right Cessation
- 2002-06-07 WO PCT/ES2002/000281 patent/WO2002102406A1/en active IP Right Grant
- 2002-06-07 PT PT02738185T patent/PT1402898E/en unknown
- 2002-06-07 US US10/480,538 patent/US7022668B2/en not_active Expired - Lifetime
- 2002-06-07 MX MXPA03011622A patent/MXPA03011622A/en active IP Right Grant
- 2002-06-07 CA CA2449910A patent/CA2449910C/en not_active Expired - Lifetime
- 2002-06-07 DE DE60202474T patent/DE60202474T2/en not_active Expired - Lifetime
- 2002-06-07 JP JP2003504992A patent/JP4252444B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2181592A1 (en) | 2003-02-16 |
| BR0210428A (en) | 2004-08-17 |
| BRPI0210428B8 (en) | 2021-05-25 |
| PT1402898E (en) | 2005-05-31 |
| US7022668B2 (en) | 2006-04-04 |
| EP1402898B1 (en) | 2004-12-29 |
| ES2236525T3 (en) | 2005-07-16 |
| DE60202474T2 (en) | 2005-12-29 |
| WO2002102406A1 (en) | 2002-12-27 |
| JP4252444B2 (en) | 2009-04-08 |
| KR20040030675A (en) | 2004-04-09 |
| CA2449910C (en) | 2013-01-08 |
| EP1402898A1 (en) | 2004-03-31 |
| BRPI0210428B1 (en) | 2018-04-17 |
| MXPA03011622A (en) | 2004-07-01 |
| JP2004534076A (en) | 2004-11-11 |
| ATE285787T1 (en) | 2005-01-15 |
| DE60202474D1 (en) | 2005-02-03 |
| US20040242466A1 (en) | 2004-12-02 |
| ES2181592B1 (en) | 2003-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2449910C (en) | Use of glycoprotein for the treatment and re-epithelialisation of wounds | |
| US5591709A (en) | Compositions and methods for treating wounds | |
| US4889844A (en) | Fructose containing wound healing preparation | |
| NZ223520A (en) | Wound healing pharmaceutical formulation comprising insulin-like growth factor-ii (igf-ii) | |
| EP0650366B1 (en) | Compositions and methods for treating wounds | |
| EP3017808B1 (en) | Water-soluble hyaluronic acid gel and method for producing same | |
| US20090137458A1 (en) | Methods and compositions for increasing skin remodeling | |
| US5177065A (en) | Monosaccharide containing wound healing preparation | |
| CA2246773A1 (en) | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction | |
| JPH08503462A (en) | Compositions of oak bark extract, related synthetic compositions and methods of using same | |
| US10456366B2 (en) | Composition and methods for tissue regeneration | |
| EP0221728A2 (en) | Monosaccharide containing wound healing preparation | |
| AU621368B2 (en) | Pharmaceutical composition containing deoxyribonucleosides and/or deoxyribonucleotides for wound healing | |
| CA2225898A1 (en) | Enhancing keratinocyte migration and proliferation | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| EP0343671B1 (en) | Pharmaceutical composition for the treatment of skin wounds | |
| CN117100635A (en) | Active preparation suitable for repairing cell tissues | |
| US10292997B2 (en) | Compositions and methods for stimulating wound healing | |
| CN111821504B (en) | Silver ion disinfection gel and preparation method thereof | |
| CA1292943C (en) | Monosaccharide containing wound healing preparation | |
| CA2100314C (en) | Pharmaceutical composition for the treatment of chronic skin ulcers | |
| JPS63215631A (en) | wound treatment agent | |
| KR100231805B1 (en) | Topical formulations containing human epidermal growth factor | |
| TWM656940U (en) | Liposome-coated structure with plant-derived bioactive peptides | |
| KR20250019788A (en) | A hydrogel composition for removing skin keratin, and a patch comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220607 |